Nanodiamond-DGEA peptide conjugates for enhanced delivery of doxorubicin to prostate cancer

• Amanee D Salaam,
• Patrick Hwang,
• Roberus McIntosh,
• Hadiyah N Green,
• Ho-Wook Jun and
• Derrick Dean

Beilstein J. Nanotechnol. 2014, 5, 937–945, doi:10.3762/bjnano.5.107

• delivery system for bone metastatic prostate cancer was developed, characterized, and evaluated in vitro. NDs were conjugated with the Asp–Gly–Glu–Ala (DGEA) peptide to target α2β1 integrins over-expressed in prostate cancers during metastasis. To facilitate drug delivery, DOX was adsorbed to the surface

• work, we developed a novel ND meditated drug delivery system to increase specificity of DOX by utilizing DGEA to target the α2β1 integrins overexpressed in metastatic prostate cancers. ND-DGEA conjugates and the ND-DGEA+DOX system were synthesized and evaluated for multifunctional applications (i.e

• effects of the drug delivery system were due to the combination of enhanced targeting and drug delivery instead of potential toxicity of ND or DGEA peptide, PC3 cells were also exposed to ND, ND-DGEA, and free DGEA. The cell viability was quantified with a 3-(4,5-dimethylthiazol-2-yl)-5-(3

Near-infrared dye loaded polymeric nanoparticles for cancer imaging and therapy and cellular response after laser-induced heating

• Tingjun Lei,
• Alicia Fernandez-Fernandez,
• Romila Manchanda,
• Yen-Chih Huang and
• Anthony J. McGoron

Beilstein J. Nanotechnol. 2014, 5, 313–322, doi:10.3762/bjnano.5.35

• after background subtraction). The ratio R was then determined by normalizing the total pixel intensity of this region of interest to its total area. HT treatment Two different heating modes, namely (1) an incubator and (2) a laser/NP HT delivery system, were used for in vitro studies. Detailed

Magnetic-Fe/Fe₃O₄-nanoparticle-bound SN38 as carboxylesterase-cleavable prodrug for the delivery to tumors within monocytes/macrophages

• Hongwang Wang,
• Tej B. Shrestha,
• Matthew T. Basel,
• Raj K. Dani,
• Gwi-Moon Seo,
• Sivasai Balivada,
• Marla M. Pyle,
• Heidy Prock,
• Olga B. Koper,
• Prem S. Thapa,
• David Moore,
• Ping Li,
• Viktor Chikan,
• Deryl L. Troyer and
• Stefan H. Bossmann

Beilstein J. Nanotechnol. 2012, 3, 444–455, doi:10.3762/bjnano.3.51

• physiological conditions, which is highly desired for a cell-based delivery system. We have established that when Mo/Ma cells are used as carriers, the tumor-homing process takes about one day. Their robust stability will ensure the integrity of the MNPs after delivery to the tumor site. The uptake efficiency